Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.
Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, Gelsomino F, Brizzi MP, Di Meglio G, Spada F, Tamberi S, Lolli I, Cives M, Marconcini R, Pucci F, Berardi R, Antonuzzo L, Badalamenti G, Santini D, Recine F, Vanni S, Tebaldi M, Severi S, Rudnas B, Nanni O, Ranallo N, Crudi L, Calabrò L, Ibrahim T. Bongiovanni A, et al. Among authors: leo s. Eur J Cancer. 2024 Sep;208:114129. doi: 10.1016/j.ejca.2024.114129. Epub 2024 May 25. Eur J Cancer. 2024. PMID: 39002347 Free article. Clinical Trial.
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.
Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, Satolli MA, Bertocchi P, Catalano V, Giommoni E, Comandone A, Maiello E, Riccardi F, Ferrara R, Trogu A, Berardi R, Leo S, Bertolini A, Angelini F, Cinieri S, Russo A, Pisconti S, Brunetti AE, Azzariti A, Santini D. Silvestris N, et al. Among authors: leo s. PLoS One. 2013 Oct 28;8(10):e74402. doi: 10.1371/journal.pone.0074402. eCollection 2013. PLoS One. 2013. PMID: 24204569 Free PMC article.
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.
Passardi A, Scarpi E, Cavanna L, Dall'Agata M, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Brandes AA, Tenti E, Vespignani R, Frassineti GL, Amadori D, De Giorgi U. Passardi A, et al. Among authors: leo s. Oncotarget. 2016 May 31;7(22):33210-9. doi: 10.18632/oncotarget.8901. Oncotarget. 2016. PMID: 27120807 Free PMC article. Clinical Trial.
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial.
Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A. Casadei Gardini A, et al. Among authors: leo s. Onco Targets Ther. 2018 Aug 29;11:5261-5268. doi: 10.2147/OTT.S166614. eCollection 2018. Onco Targets Ther. 2018. PMID: 30214231 Free PMC article.
Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A, Di Maio S, Mocerino C, Ottaviano M, De Divitiis C, Guarnotta V, Dolce P, Modica R, Puliafito I, Tozzi L, Di Sarno A, Leo S, Riccardi F, Palmieri G, Tafuto S, Bianco A, Badalamenti G, Colao A; ELIOS. Faggiano A, et al. Among authors: leo s. Endocrine. 2019 Nov;66(2):417-424. doi: 10.1007/s12020-019-01894-0. Epub 2019 Mar 14. Endocrine. 2019. PMID: 30875056
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Bongiovanni A, et al. Among authors: leo s. BMJ Open. 2020 Jul 19;10(7):e034393. doi: 10.1136/bmjopen-2019-034393. BMJ Open. 2020. PMID: 32690499 Free PMC article.
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Biganzoli L, Cinieri S, Berardi R, Pedersini R, McCartney A, Minisini AM, Caremoli ER, Spazzapan S, Magnolfi E, Brunello A, Risi E, Palumbo R, Leo S, Colleoni M, Donati S, De Placido S, Orlando L, Pistelli M, Parolin V, Mislang A, Becheri D, Puglisi F, Sanna G, Zafarana E, Boni L, Mottino G. Biganzoli L, et al. Among authors: leo s. Breast Cancer Res. 2020 Aug 5;22(1):83. doi: 10.1186/s13058-020-01319-1. Breast Cancer Res. 2020. PMID: 32758299 Free PMC article. Clinical Trial.
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
Cascinu S, Berardi R, Bianco R, Bilancia D, Zaniboni A, Ferrari D, Mosconi S, Spallanzani A, Cavanna L, Leo S, Negri F, Beretta GD, Sobrero A, Banzi M, Morabito A, Bittoni A, Marciano R, Ferrara D, Noventa S, Piccirillo MC, Labianca R, Mosconi C, Casadei Gardini A, Gallo C, Perrone F. Cascinu S, et al. Among authors: leo s. Eur J Cancer. 2021 May;148:422-429. doi: 10.1016/j.ejca.2021.02.023. Epub 2021 Mar 31. Eur J Cancer. 2021. PMID: 33812334 Clinical Trial.
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.
Colucci G, Maiello E, Gebbia V, Giuliani F, Serravezza G, Lelli G, Leo S, Filippelli G, Nicolella G, Brandi M. Colucci G, et al. Among authors: leo s. Cancer. 1999 Feb 1;85(3):535-45. Cancer. 1999. PMID: 10091727 Clinical Trial.
599 results